enGene Therapeutics Inc. · NASDAQ:ENGN

enGene Therapeutics Inc. financial statements

enGene Therapeutics Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Research and development94.5M38.3M16.5M15.5M
Operating income-123.2M-62.3M-26.1M-19.4M
Depreciation and amortization500.0K300.0K200.0K200.0K
EBITDA-122.7M-62.0M-25.9M-19.2M
Interest expense2.99M2.80M4.95M1.42M
Income before tax-117.3M-55.2M-99.9M-24.4M
Income tax0-19.0K17.0K22.0K
Net income-117.3M-55.1M-99.9M-24.5M
Earnings per share, basic2.291.46151.2244.30
Earnings per share, diluted2.291.46151.2244.30

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents50.2M173.0M81.5M20.4M
Short-term investments143.6M65.3M
Current assets201.4M247.4M85.4M22.6M
Property, plant and equipment2.48M1.17M589.0K387.0K
Total assets221.5M311.2M87.0M23.9M
Accounts payable6.69M1.41M1.16M723.0K
Current liabilities32.0M14.7M5.26M5.10M
Total liabilities53.8M38.6M14.5M47.4M
Shareholders' equity167.7M272.6M72.5M-76.6M
Shares outstanding52.0M51.0M23.2M665.8K

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-99.2M-48.3M-24.7M-17.6M
Capital spending-1.49M-925.0K-318.0K-153.0K
Free cash flow-100.7M-49.2M-25.1M-17.7M
Cash from investing-25.1M-126.0M-318.0K-153.0K
Cash from financing1.52M265.7M86.1M28.0M
Dividends paid0
Change in cash-122.9M91.5M61.1M9.42M